Neurofeedback to Improve Spasticity After Incomplete Spinal Cord Injury
Exploring the Effects of Neurofeedback on Spasticity and Motor Function in Individuals With Subacute and Chronic Incomplete Spinal Cord Injury
2 other identifiers
interventional
20
1 country
1
Brief Summary
After incomplete spinal cord injury (iSCI), many people still have control over their upper and/or lower limbs, but secondary conditions such as spasticity impair the function they have left. Spasticity includes increased reflex response and muscle tone, and is often painful. In this study we want to test a rehabilitation therapy to reduce spasticity after iSCI and improve participants' control over their extremities. The study involves recording participants' brain signals (EEG) and displaying them on a computer, so that they learn to control specific features derived from their brain waves. This is called neurofeedback (NF). Two studies conducted in our group that explored NF effect on central neuropathic pain in iSCI reported as incidental finding a decrease in spasms, muscle tightness and foot drop. The effect of NF is immediate and lasts up to 24 hours. In this study, we will explore systematically the short- and medium-term effect of NF on a larger number of iSCI, to inform a potential randomized clinical trial. Gaining control over one's brain activity requires practice and 80-90% people eventually learn the skill. Each participant will therefore attend five sessions of NF taking no longer than two hours each. 20 participants will be recruited and assigned to either upper or lower limb spasticity groups. This will allow us to determine if the mechanism of NF differs between arms and legs. Participants will be further grouped into sub-acute and chronic groups, depending on the time since injury, to pinpoint at what stage post-injury NF is the most effective. All groups will receive the same number of NF sessions. The primary outcome of this study is the change in spasticity of the hand or leg, as measured by the Modified Ashworth Scale (MAS). Secondary outcomes include use of arm/leg, quality of life, and the relation between functional improvement and EEG changes. Outcomes will be compared before/after each session, and before/after the whole intervention period, both inter- and intra-group.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Aug 2021
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 15, 2021
CompletedFirst Posted
Study publicly available on registry
April 19, 2021
CompletedStudy Start
First participant enrolled
August 31, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2023
CompletedApril 18, 2022
April 1, 2022
1.7 years
April 15, 2021
April 11, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
Modified Ashworth Scale
Improvements in spasticity in the upper or lower limb (UL, LL groups) after neurofeedback sessions
4 weeks
Secondary Outcomes (3)
Functional improvements
4 weeks
Participant experience
1 hour; after the last experimental session
Correlation between EEG activity and functional improvements
one day to one month after the last experimental session, off line quantitative analysis
Study Arms (4)
Upper limb subacute spinal cord injury (sUL)
EXPERIMENTALIntervention: neurofeedback. Participants will receive visual feedback on a screen. Diagnostic Tests: Modified Ashworth Scale grading muscle resistance to movement (all limbs tested) Perceived Spasticity level questionnaire on impact of spasticity Spinal Cord Independence Measure questionnaire on level of independence of patients Diary of spastic episodes Grip strength - measure of hand and forearm muscle strength using dynamometer Instrumented Pendulum test - oscillations when forearm is dropped from a resting position Hand grip - closing and opening the fist recorded with Kinect (Microsoft) device EEG recording in relaxed state with bioamplifier g.usbamp (Guger Technologies, Austria) Brief Visual Analog Scale self-assessment of performance and mental strategies Motor evoked potential - effect of therapy on the descending path from brain to spinal cord with a transcranial magnetic stimulator (200-2, Magstim Co Ltd)
Upper limb chronic spinal cord injury (sUL)
EXPERIMENTALIntervention: neurofeedback. Participants will receive visual feedback on a screen. Diagnostic Tests: Modified Ashworth Scale grading muscle resistance to movement (all limbs tested) Perceived Spasticity level questionnaire on impact of spasticity Spinal Cord Independence Measure questionnaire on level of independence of patients Diary of spastic episodes Grip strength - measure of hand and forearm muscle strength using dynamometer Instrumented Pendulum test - oscillations when forearm is dropped from a resting position Hand grip - closing and opening the fist recorded with Kinect (Microsoft) device EEG recording in relaxed state with bioamplifier g.usbamp (Guger Technologies, Austria) Brief Visual Analog Scale self-assessment of performance and mental strategies Motor evoked potential - effect of therapy on the descending path from brain to spinal cord with a transcranial magnetic stimulator (200-2, Magstim Co Ltd)
Lower limb subacute spinal cord injury (sLL)
EXPERIMENTALIntervention: neurofeedback. Participants will receive visual feedback on a screen. Diagnostic Tests: Modified Ashworth Scale grading muscle resistance to movement (all limbs tested) Perceived Spasticity level questionnaire on impact of spasticity Spinal Cord Independence Measure questionnaire on level of independence of patients Diary of spastic episodes Instrumented Pendulum test - oscillations when lower leg is dropped from a resting position 10m walking test - patient walks 10 meters in a straight line, recorded with Kinect (Microsoft) device EEG recording in relaxed state with bioamplifier g.usbamp (Guger Technologies, Austria) Brief Visual Analog Scale self-assessment of performance and mental strategies Motor evoked potential - effect of therapy on the descending path from brain to spinal cord with a transcranial magnetic stimulator (200-2, Magstim Co Ltd)
Lower limb chronic spinal cord injury (cLL)
EXPERIMENTALIntervention: neurofeedback. Participants will receive visual feedback on a screen. Diagnostic Tests: Modified Ashworth Scale grading muscle resistance to movement (all limbs tested) Perceived Spasticity level questionnaire on impact of spasticity Spinal Cord Independence Measure questionnaire on level of independence of patients Diary of spastic episodes Instrumented Pendulum test - oscillations when lower leg is dropped from a resting position 10m walking test - patient walks 10 meters in a straight line, recorded with Kinect (Microsoft) device EEG recording in relaxed state with bioamplifier g.usbamp (Guger Technologies, Austria) Brief Visual Analog Scale self-assessment of performance and mental strategies Motor evoked potential - effect of therapy on the descending path from brain to spinal cord with a transcranial magnetic stimulator (200-2, Magstim Co Ltd)
Interventions
Neurofeedback is a neuromodulatory intervention that does not require applying external stimuli. It relies on displaying participants' brain activity in real time, with the aim of modifying it. Electrical activity (EEG) will be recorded from participants and displayed in real time on a computer screen, in the form of three bars. They will be asked to increase the middle bar, while keeping the side bars low. The intervention requires training to achieve voluntary control of the targeted brain activity.
Eligibility Criteria
You may qualify if:
- Aged above 18
- Incomplete injury to the spinal cord, resulting in ASIA level C or D SCI
- Injury occurred no more than six months prior to participation in the study
- Injury level C3 to C7
- Normal or corrected to normal vision
- Spasticity equivalent of MAS level 1+ and above
- Aged above 18
- Incomplete injury to the spinal cord, resulting in ASIA level C or D SCI
- Injury occurred more than one year prior to participation in the study
- Injury level C3 to C7
- Normal or corrected to normal vision
- Spasticity equivalent of MAS level 1+ and above
- Live in Greater Glasgow and Clyde area
- Aged above 18
- Incomplete injury to the spinal cord, resulting in ASIA level C or D SCI
- +13 more criteria
You may not qualify if:
- Participation in any other neurofeedback intervention group
- Inability to understand the task
- Self-reported neurological disorders e.g. previously confirmed peripheral nerve injury or brain injury
- General poor health due to secondary consequences of injury
- Conditions contra-indicative of neurostimulator usage (implanted devices, sensitive skin sores in the upper and lower extremities, pregnancy, severe autonomic dysreflexia)
- History of epilepsy
- Inability to sit for 1.5 hours
- Inability to speak and/or understand English
- Participation in any other neurofeedback intervention group
- Inability to understand the task
- Self-reported neurological disorders e.g. previously confirmed peripheral nerve injury or brain injury
- General poor health due to secondary consequences of injury
- Conditions contra-indicative of neurostimulator usage (implanted devices, sensitive skin sores in the upper and lower extremities, pregnancy, severe autonomic dysreflexia)
- History of epilepsy
- Inability to sit for 1.5 hours
- +2 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Queen Elizabeth University Hospital, Queen Elizabeth National Spinal Injurie Unit
Glasgow, Glasgow City, G51 4TF, United Kingdom
Study Officials
- PRINCIPAL INVESTIGATOR
Mariel Purcell, MD
NHS Greater Galsgow and Clyde
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 15, 2021
First Posted
April 19, 2021
Study Start
August 31, 2021
Primary Completion
May 1, 2023
Study Completion
July 1, 2023
Last Updated
April 18, 2022
Record last verified: 2022-04
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL
- Time Frame
- After study end (March 2023)
- Access Criteria
- Data will be shared upon reasonable request
Shared on request